Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

123I-异氟烷特性和18F-FDGPET联合用于神经退行性疾病中运动和认知相关障碍的表征

卷 18, 期 3, 2021

发表于: 23 September, 2021

页: [196 - 207] 页: 12

弟呕挨: 10.2174/1567205018666210608112302

价格: $65

摘要

背景：运动(MD)和认知(CD)疾病都可发生在一些神经退行性疾病中，如帕金森病(PD)和阿尔茨海默病(AD)。 目的：我们进一步研究了123I-异氟烷检查和18F-FDGPET联合使用在这些疾病患者早期的有效性。 方法：回顾性纳入连续25例近期出现MD和乳糜泻临床症状的患者。所有患者均接受了神经系统检查、神经心理测试和磁共振成像。所有病例均进行123例I-异氟烷检查，两周后再进行18例F-FDGPET检查。在这两个程序中，我们都确定了定性(QL)和定量(QN)图像分析。 结果：在123例I-异氟烷检查和18例F-FDGPET病理数据的患者中，56%的病例证实了相关的多巴胺能和认知障碍。16%的病例与PET正常的病理检查可以诊断MD并排除相关的乳糜泻，尽管有临床症状。相反，28%的病例正常使用病理PET可排除基底神经节损伤，同时确诊基底神经节损伤。QN123I-异氟烷检查分析表现优于QL，因为QN正确地描述了2例QL正常的MD患者。此外，尽管有4例患者的QL怀疑存在低代谢区域，但只有对18例F-FDGPET进行QN分析，才能对正常代谢进行正确的分类。 结论：结合这些影像学方法是早期准确识别和描述MD和乳糜泻的可靠诊断工具。QN分析对支持QL评价有效，建议其常规使用，特别是不确定的QL。

关键词: 运动障碍，认知障碍，123i-异氟烷方面，18F-FDGPET，定性分析，定量分析。

« Previous Next »
[1]
Baldacci F, Lista S, O’Bryant SE, Ceravolo R, Toschi N, Hampel H. Blood-based biomarker screening with agnostic biological definitions for an accurate diagnosis within the dimensional spectrum of neurodegenerative diseases. Methods Mol Biol 2018; 1750: 139-55.
[http://dx.doi.org/10.1007/978-1-4939-7704-8_9] [PMID: 29512070]
[2]
Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: Critical review of PD-MCI. Mov Disord 2011; 26(10): 1814-24.
[http://dx.doi.org/10.1002/mds.23823] [PMID: 21661055]
[3]
Foguem C, Manckoundia P. Lewy body disease: Clinical and pathological “Overlap Syndrome” Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). Curr Neurol Neurosci Rep 2018; 18(5): 24.
[http://dx.doi.org/10.1007/s11910-018-0835-5] [PMID: 29629495]
[4]
Fares A, Borrmann D. Neurochemical aspects of Alzheimer’s disease and movement disturbances: A theory of β-Amyloid and τ-Protein. Am J Alzheimers Dis Other Demen 2018; 33(8): 535-40.
[http://dx.doi.org/10.1177/1533317518790631] [PMID: 30045626]
[5]
Woodward M, Mackenzie IRA, Hsiung G-YR, Jacova C, Feldman H. Multiple brain pathologies in dementia are common. Eur Geriatr Med 2010; 5(1): 259-65.
[http://dx.doi.org/10.1016/j.eurger.2010.07.012]
[6]
Das S, Zhang Z, Ang LC. Clinicopathological overlap of neurodegenerative diseases: A comprehensive review. J Clin Neurosci 2020; 78: 30-3.
[7]
Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014; 83(5): 406-12.
[http://dx.doi.org/10.1212/WNL.0000000000000641] [PMID: 24975862]
[8]
Joutsa J, Gardberg M, Röyttä M, Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord 2014; 20(8): 840-4.
[http://dx.doi.org/10.1016/j.parkreldis.2014.04.019] [PMID: 24816002]
[9]
Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol 2006; 5(1): 75-86.
[http://dx.doi.org/10.1016/S1474-4422(05)70285-4] [PMID: 16361025]
[10]
Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord 2010; 25(3): 357-62.
[http://dx.doi.org/10.1002/mds.22977] [PMID: 20108379]
[11]
Respondek G, Roeber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013; 28(4): 504-9.
[http://dx.doi.org/10.1002/mds.25327] [PMID: 23436751]
[12]
Hellwig S, Frings L, Amtage F, et al. 18F-FDG PET is an early predictor of overall survival in suspected atypical parkinsonism. J Nucl Med 2015; 56(10): 1541-6.
[http://dx.doi.org/10.2967/jnumed.115.159822] [PMID: 26229141]
[13]
Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010; 9(1): 119-28.
[http://dx.doi.org/10.1016/S1474-4422(09)70299-6] [PMID: 20083042]
[14]
Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson associated risk syndrome study. Neurology 2014; 83(19): 1739-46.
[http://dx.doi.org/10.1212/WNL.0000000000000960] [PMID: 25298306]
[15]
Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson’s disease. J Parkinsons Dis 2015; 5(4): 681-97.
[http://dx.doi.org/10.3233/JPD-150685] [PMID: 26485429]
[16]
Mirpour S, Turkbey EB, Marashdeh W, El Khouli R, Subramaniam RM. Impact of DAT-SPECT on management of patients suspected of Parkinsonism. Clin Nucl Med 2018; 43(10): 710-4.
[http://dx.doi.org/10.1097/RLU.0000000000002240] [PMID: 30153144]
[17]
Brooks DJ, Pavese N. Imaging biomarkers in Parkinson’s disease. Prog Neurobiol 2011; 95(4): 614-28.
[http://dx.doi.org/10.1016/j.pneurobio.2011.08.009] [PMID: 21896306]
[18]
Palumbo B, Fravolini ML, Nuvoli S, et al. Comparison of two neural network classifiers in the differential diagnosis of essential tremor and Parkinson’s disease by (123)I-FP-CIT brain SPECT. Eur J Nucl Med Mol Imaging 2010; 37(11): 2146-53.
[http://dx.doi.org/10.1007/s00259-010-1481-6] [PMID: 20567820]
[19]
Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 2013; 20(1): 16-34.
[http://dx.doi.org/10.1111/ene.12022] [PMID: 23279440]
[20]
Nuvoli S, Palumbo B, Malaspina S, Madeddu G, Spanu A. 123I-ioflupane SPET and 123I-MIBG in the diagnosis of Parkinson’s disease and parkinsonian disorders and in the differential diagnosis between Alzheimer’s and Lewy’s bodies dementias. Hell J Nucl Med 2018; 21(1): 60-8.
[PMID: 29550847]
[21]
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89(1): 88-100.
[http://dx.doi.org/10.1212/WNL.0000000000004058] [PMID: 28592453]
[22]
McKeith I, O’Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study. Lancet Neurol 2007; 6(4): 305-13.
[http://dx.doi.org/10.1016/S1474-4422(07)70057-1] [PMID: 17362834]
[23]
Isaacson SH, Fisher S, Gupta F, et al. Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: A US perspective. Expert Rev Neurother 2017; 17(3): 219-25.
[http://dx.doi.org/10.1080/14737175.2017.1256205] [PMID: 27813429]
[24]
Pirker W, Asenbaum S, Bencsits G, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000; 15(6): 1158-67.
[http://dx.doi.org/10.1002/1531-8257(200011)15:6<1158::AID-MDS1015>3.0.CO;2-0] [PMID: 11104200]
[25]
Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 2011; 134(Pt 11): 3146-66.
[http://dx.doi.org/10.1093/brain/awr177] [PMID: 21810889]
[26]
Walker Z, Gandolfo F, Orini S, et al. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging 2018; 45(9): 1534-45.
[http://dx.doi.org/10.1007/s00259-018-4031-2] [PMID: 29779045]
[27]
Meyer PT, Frings L, Rücker G, Hellwig S. 18F-FDG PET in Parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 2017; 58(12): 1888-98.
[http://dx.doi.org/10.2967/jnumed.116.186403] [PMID: 28912150]
[28]
Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010; 37(2): 443-50.
[http://dx.doi.org/10.1007/s00259-009-1267-x] [PMID: 19838702]
[29]
Nuvoli S, Spanu A, Piras MR, et al. 123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders. Medicine (Baltimore) 2017; 96(21): e6967.
[http://dx.doi.org/10.1097/MD.0000000000006967] [PMID: 28538394]
[30]
Roberts G, Lloyd JJ, Petrides GS, et al. 123I-FP-CIT striatal binding ratios do not decrease significantly with age in older adults. Ann Nucl Med 2019; 33(6): 434-43.
[http://dx.doi.org/10.1007/s12149-019-01352-x] [PMID: 30900103]
[31]
Sabri O, Ringelstein EB, Hellwig D, et al. Neuropsychological impairment correlates with hypoperfusion and hypometabolism but not with severity of white matter lesions on MRI in patients with cerebral microangiopathy. Stroke 1999; 30(3): 556-66.
[http://dx.doi.org/10.1161/01.STR.30.3.556] [PMID: 10066852]
[32]
Frantellizzi V, Pani A, Ricci M, Locuratolo N, Fattapposta F, De Vincentis G. Neuroimaging in vascular cognitive impairment and dementia: A systematic review. J Alzheimers Dis 2020; 73(4): 1279-94.
[http://dx.doi.org/10.3233/JAD-191046] [PMID: 31929166]
[33]
Varrone A, Asenbaum S, Vander Borght T, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging 2009; 36(12): 2103-10.
[http://dx.doi.org/10.1007/s00259-009-1264-0] [PMID: 19838705]
[34]
Kovacs GG. Concepts and classification of neurodegenerative diseases. Handb Clin Neurol 2017; 145: 301-7.
[http://dx.doi.org/10.1016/B978-0-12-802395-2.00021-3] [PMID: 28987178]
[35]
Buchert R, Buhmann C, Apostolova I, Meyer PT, Gallinat J. Nuclear imaging in the diagnosis of clinically uncertain Parkinsonian syndromes. Dtsch Arztebl Int 2019; 116(44): 747-54.
[http://dx.doi.org/10.3238/arztebl.2019.0747] [PMID: 31774054]
[36]
Nuvoli S, Spanu A, Madeddu G. Brain SPECT with perfusion radiopharmaceuticals and dopaminergic system radiocompounds in dementia disorders. Curr Alzheimer Res 2017; 14(2): 143-53.
[http://dx.doi.org/10.2174/1567205013666161019144406] [PMID: 27774875]
[37]
Nuvoli S, Spanu A, Fravolini ML, et al. [123I]Metaiodobenzylguanidine (MIBG) Cardiac Scintigraphy and Automated Classification Techniques in Parkinsonian Disorders. Mol Imaging Biol 2020; 22(3): 703-10.
[http://dx.doi.org/10.1007/s11307-019-01406-6] [PMID: 31309370]
[38]
Nicastro N, Garibotto V, Burkhard PR. The role of molecular imaging in assessing degenerative parkinsonism -an updated review. Swiss Med Wkly 2018; 26 148:w14621 eCollection 2018
[39]
Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease. Clin Med (Lond) 2016; 16(4): 371-5.
[http://dx.doi.org/10.7861/clinmedicine.16-4-371] [PMID: 27481384]
[40]
Tang J, Yang B, Adams MP, et al. Artificial neural network-based prediction of outcome in Parkinson’s disease patients using DaTscan SPECT imaging features. Mol Imaging Biol 2019; 21(6): 1165-73.
[http://dx.doi.org/10.1007/s11307-019-01334-5] [PMID: 30847821]
[41]
Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26(3): 912-21.
[http://dx.doi.org/10.1016/j.neuroimage.2005.03.012] [PMID: 15955501]
[42]
Mäkinen E, Joutsa J, Johansson J, Mäki M, Seppänen M, Kaasinen V. Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism. J Neural Transm (Vienna) 2016; 123(11): 1309-18.
[http://dx.doi.org/10.1007/s00702-016-1586-6] [PMID: 27324804]
[43]
Filippi L, Manni C, Pierantozzi M, et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson’s disease with unilateral symptoms. Nucl Med Commun 2005; 26(5): 421-6.
[http://dx.doi.org/10.1097/00006231-200505000-00005] [PMID: 15838424]
[44]
Kato T, Inui Y, Nakamura A, Ito K. Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev 2016; 30: 73-84.
[http://dx.doi.org/10.1016/j.arr.2016.02.003] [PMID: 26876244]
[45]
Lehman VT, Carter RE, Claassen DO, et al. Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease. Clin Nucl Med 2012; 37(8): 721-6.
[http://dx.doi.org/10.1097/RLU.0b013e3182478d89] [PMID: 22785496]
[46]
Garibotto V, Montandon ML, Viaud CT, et al. Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin Nucl Med 2013; 38(3): e112-7.
[http://dx.doi.org/10.1097/RLU.0b013e318279b991] [PMID: 23357822]
[47]
Jolepalem P, Balon HR, Wong CY, Wu D. Complementary role of 18F-FDG PET and 123I-ioflupane SPECT in the diagnosis of Lewy body disease. J Nucl Med Technol 2014; 42(3): 233-4.
[http://dx.doi.org/10.2967/jnmt.113.133199] [PMID: 25033885]
[48]
Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 2009; 50(10): 1638-45.
[http://dx.doi.org/10.2967/jnumed.109.065870] [PMID: 19759102]
[49]
Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm (Vienna) 2002; 109(3): 329-39.
[http://dx.doi.org/10.1007/s007020200027] [PMID: 11956955]
[50]
Li X, James S, Lei P. Interactions between α-synuclein and tau protein: Implications to neurodegenerative disorders. J Mol Neurosci 2016; 60(3): 298-304.
[http://dx.doi.org/10.1007/s12031-016-0829-1] [PMID: 27629562]
[51]
Armstrong RA, Lantos PL, Cairns NJ. Overlap between neurodegenerative disorders. Neuropathology 2005; 25(2): 111-24.
[http://dx.doi.org/10.1111/j.1440-1789.2005.00605.x] [PMID: 15875904]

Rights & Permissions Print Cite
Article Metrics
17
© 2024 Bentham Science Publishers | Privacy Policy